Crispr Therapeutics AG (NASDAQ: CRSP) net income
Crispr Therapeutics AG reported a net loss of $581.6m for fiscal 2025; in fiscal 2024 it reported a net loss of $366.3m. Earnings per share were −$6.47.
Crispr Therapeutics AG's best year of the last 10 was fiscal 2021. It reported a loss in 8 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$581.6m | — | −16,569.8% | −$6.47 |
| 2024 | −$366.3m | — | −981.5% | −$4.34 |
| 2023 | −$153.6m | — | −41.4% | −$1.94 |
| 2022 | −$650.2m | −272.2% | −54,271.7% | −$8.36 |
| 2021 | $377.7m | — | 41.3% | $4.97 |
| 2020 | −$348.9m | −621.8% | −48,520.9% | −$5.29 |
| 2019 | $66.9m | — | 23.1% | $1.23 |
| 2018 | −$165.0m | — | −5,281.1% | −$3.44 |
| 2017 | −$68.4m | — | −166.7% | −$1.71 |
| 2016 | −$23.2m | — | −448.8% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Crispr Therapeutics AG net income compared with its sector
By net income for its latest fiscal year, Crispr Therapeutics AG ranks 480th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Crispr Therapeutics AG, −16,569.8%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 478th | Pacific Biosciences of California | −$546.4m | −341.5% |
| 479th | Ultragenyx Pharmaceutical | −$575.0m | −85.4% |
| 480th | Crispr Therapeutics AG | −$581.6m | −16,569.8% |
| 481st | Dentsply Sirona | −$598.0m | −16.3% |
| 482nd | Recursion Pharmaceuticals | −$644.8m | −863.4% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Crispr Therapeutics AG
- How much did Crispr Therapeutics AG earn in fiscal 2025?
- Crispr Therapeutics AG reported a net loss of $581.6m for fiscal 2025. In fiscal 2024 it reported a net loss of $366.3m.
- What are the earnings per share of Crispr Therapeutics AG?
- They were −$6.47 in fiscal 2025, compared with −$4.34 in fiscal 2024.
- What was the most profitable year for Crispr Therapeutics AG?
- Of its last 10 fiscal years, fiscal 2021, with $377.7m.
- Where does Crispr Therapeutics AG rank in its sector by net income?
- It ranks 480th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Crispr Therapeutics AG come from?
- From the annual report (Form 10-K) that Crispr Therapeutics AG files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Crispr Therapeutics AG files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Crispr Therapeutics AG: the Crispr Therapeutics AG page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.